You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

September 12, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA approves oral iron-based drug for dialysis patients with hyperphosphatemia

FDA has approved Ferric Citrate (Keryx), an oral, iron-based therapy for the control of serum phosphorus levels in chronic kidney disease patients on dialysis.
» Read about this newly approved drug

Investigational ER oral formulation of hydrocodone, acetaminophen shows efficacy in acute pain trial

An investigational extended-release oral formulation of hydrocodone and acetaminophen for treatment of moderate to moderately severe acute pain was more effective than placebo at providing rapid and consistent pain relief in patients 48 hours post-surgery, according to new data.
» Read about the phase 3 study presented at PAINWeek 2014

Continuing Education

MTM essentials for anticoagulant management in cardiovascular disease

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the pharmacological properties, safety and efficacy, and risk/benefit profile for the various anticoagulant medications used in cardiovascular diseases.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT10-VXP89.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Drugs in Perspective: Dalvance

Dalbavancin is recognized as an innovative treatment option for acute bacterial skin and skin structure infections that provides an equally unique 2-dose regimen for this serious infection compared to the routine once-daily or twice-intravenous antibiotics.
» See more

 

Related Articles

Chronic kidney disease: new clinical guidelines from the American College of Physicians

Investigational heart failure drug cut cardiovascular deaths by 20% vs. ACE-inhibitor in study

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group